Imunon, Inc.

Imunon, Inc. Stock Forecast & Price Prediction

Live Imunon, Inc. Stock (IMNN) Price
$1.14

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$1.14

P/E Ratio

-0.53

Volume Traded Today

$295,770

Dividend

Dividends not available for IMNN

52 Week High/low

3.65/0.48

Imunon, Inc. Market Cap

$15.7M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $IMNN ๐Ÿ›‘

Before you buy IMNN you'll want to see this list of ten stocks that have huge potential. Want to see if IMNN made the cut? Enter your email below

IMNN Summary

The Imunon, Inc. (IMNN) share price is expected to increase by 821.05% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered IMNN. Price targets range from $8 at the low end to $14 at the high end. The current analyst consensus for IMNN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

IMNN Analyst Ratings

IMNN is a stock in Health Care which has been forecasted to be worth $10.5 as an average. On the higher end, the forecast price is $14 USD by Emily Bodnar from HC Wainwright & Co. and on the lower end IMNN is forecasted to be $8 by from .

IMNN stock forecast by analyst

These are the latest 20 analyst ratings of IMNN.

Analyst/Firm

Rating

Price Target

Change

Date

Emily Bodnar
HC Wainwright & Co.

Buy

$14

Reiterates

Aug 15, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$14

Maintains

Aug 5, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$12

Maintains

May 14, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$13

Maintains

Apr 1, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$12

Reiterates

Mar 13, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$12

Reiterates

Sep 15, 2023
Emily Bodnar
HC Wainwright & Co.

Buy

$12

Reiterates

Aug 11, 2023
Emily Bodnar
HC Wainwright & Co.

Buy

$12

Reiterates

May 12, 2023
James Molloy
Alliance Global Partners

Buy

$15

Initiates

Oct 13, 2022

HC Wainwright & Co.

Buy


Initiates

Apr 13, 2022

IMNN Company Information

  • Company Overview: Imunon, Inc. is a clinical-stage biotechnology company focused on immunotherapies and vaccines.
  • Primary Focus: Development of treatments for cancer and infectious diseases.
  • Lead Product: IMNN-001, a DNA-based immunotherapy for localized ovarian cancer, currently in Phase II clinical development.
  • Preclinical Products:
    • IMNN-101: COVID-19 booster vaccine.
    • IMNN-102: Treatment for Lassa virus.
    • IMNN-201: Trp2 tumor-associated antigen cancer vaccine targeting melanoma.
  • Non-Viral DNA Technology: Development across four modalities:
    • TheraPlas: Coding of proteins and cytokines for solid tumor treatment.
    • PlaCCine: Coding of viral antigens for strong immunological response.
    • FixPlas: Production of universal cancer vaccines.
    • IndiPlas: Discovery phase for personalized or neoepitope cancer vaccines.
  • Company History: Formerly known as Celsion Corporation; rebranded to Imunon, Inc. in September 2022.
  • Founded: Established in 1982.
  • Headquarters: Located in Lawrenceville, New Jersey.
IMNN
Imunon, Inc. (IMNN)

When did it IPO

N/A

Staff Count

33

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Stacy R. Lindborg Ph.D.

Market Cap

$15.7M

Imunon, Inc. (IMNN) Financial Data

In 2023, IMNN generated $0 in revenue, which was a decrease of -100.00% from the previous year. This can be seen as a signal that IMNN's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$500,000

Revenue From 2021

$500,000

0.00 %
From Previous Year

Revenue From 2022

$500,000

0.00 %
From Previous Year

Revenue From 2023

$0

-100.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -64.7%
  • Return on equity TTM -143.2%
  • Profit Margin 0.0%
  • Book Value Per Share 0.40%
  • Market capitalisation $15.7M
  • Revenue for 2021 $500,000
  • Revenue for 2022 $500,000
  • Revenue for 2023 $0
  • EPS this year (TTM) $-1.91

Imunon, Inc. (IMNN) Latest News

No news data available.

...

IMNN Frequently asked questions

The highest forecasted price for IMNN is $14 from Emily Bodnar at HC Wainwright & Co..

The lowest forecasted price for IMNN is $8 from from

The IMNN analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.